INVA NASDAQ
Innoviva, Inc.
1W: -1.6%
1M: -1.4%
3M: -3.2%
YTD: +5.4%
1Y: +18.2%
3Y: +63.1%
5Y: +27.6%
$20.94
-0.11 (-0.52%)
Weekly Expected Move ±3.5%
$19
$20
$21
$21
$22
Credit Risk of going bust: lower than 82% of companies Debt: 15.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.21 (down 99%), Innoviva, Inc. would be worth roughly what it owes.
Total debt $269.7M against a stock market value of $1.51B.
Distance to default 10.31 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $129.2M (short-term plus half of long-term), stock volatility 26.8%; Altman Z'' 9.09. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.21 (down 99%), Innoviva, Inc. would be worth roughly what it owes.
Total debt $269.7M against a stock market value of $1.51B.
Distance to default 10.31 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $129.2M (short-term plus half of long-term), stock volatility 26.8%; Altman Z'' 9.09. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
17 relationships15
As Filer
counterparties named
2
As Counterparty
mentioned by others
5
Rel. Types
2021-05-20
Earliest Filing
2022-08-22
Latest Filing
investor: 5
target: 4
acquirer: 3
partner: 2
customer: 1
Counterparties (Filed by INVA)
15 relationshipsCompanies named in INVA's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| La Jolla Pharmaceutical Company | — | target | Target company acquired by Innoviva, Inc. in a merger completed on August 22, 2022. | 2022-08-22 | View |
| Theravance Respiratory Company, LLC | — | target | Seller of 750 Class A Units and 750 Class C Units in an equity purchase agreement | 2022-07-20 | View |
| Royalty Pharma Investments 2019 ICAV | RPRX | acquirer | Purchaser of 750 Class A Units and 750 Class C Units from Theravance Respiratory Company, LLC | 2022-07-20 | View |
| Royalty Pharma Investments 2019 ICAV | RPRX | acquirer | Acquired 100% of Theravance Respiratory Company, LLC from Innoviva and Theravance Biopharma Inc. | 2022-07-13 | View |
| Theravance Biopharma Inc. | TBPH | partner | Sold its 85% ownership interest in Theravance Respiratory Company, LLC to Royalty Pharma Investments 2019 ICAV. | 2022-07-13 | View |
| Glaxo Group Limited | — | partner | Collaboration partner with Innoviva and Theravance Respiratory Company, LLC; granted releases and amended collaboration | 2022-07-13 | View |
| La Jolla Pharmaceutical Company | — | target | Target company in the merger agreement where Innoviva will acquire all outstanding shares via a tender offer. | 2022-07-11 | View |
| Tang Capital Partners, LP | — | investor | Supporting stockholder that entered into a Support Agreement to tender shares and support the merger. | 2022-07-11 | View |
| Kevin C. Tang Foundation | — | investor | Supporting stockholder that entered into a Support Agreement to tender shares and support the merger. | 2022-07-11 | View |
| Entasis Therapeutics Holdings Inc. | — | target | Target company in a merger agreement where Innoviva will acquire all outstanding shares via a tender offer. | 2022-05-24 | View |
| ISP Fund LP | — | investor | Received a distribution from Strategic Partners and entered into a letter agreement regarding capital contribution. | 2022-04-01 | View |
| Sarissa Capital Fund GP LP | — | investor | Entered into a letter agreement with Strategic Partners and ISP Fund LP regarding capital contribution. | 2022-04-01 | View |
| Glaxo Group Limited | — | acquirer | Purchased shares from Innoviva, Inc. pursuant to a Share Repurchase Agreement. | 2021-05-26 | View |
| Glaxo Group Limited | GSK | customer | Seller of Innoviva common stock in a share repurchase agreement | 2021-05-20 | View |
| Sarissa Capital Fund GP LP | — | investor | Party to Letter Agreement with Innoviva Strategic Partners LLC and ISP Fund LP | 2021-05-20 | View |
Mentioned As Counterparty
2 mentionsOther companies that named INVA in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-05 | Earnings Release; Exhibits | View | |
| 2026-05-18 | Officer/Director Change; Exhibits | View | |
| 2026-05-06 | Earnings Release; Exhibits | View | |
| 2026-05-04 | Shareholder Vote | View | |
| 2026-02-25 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-05-21 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-26 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-05-13 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2024-05-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-04-30 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2024-02-29 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2023-08-25 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2023-08-07 | Notice of Delisting or Transfer | View | |
| 2023-08-02 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2023-07-11 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2023-05-24 | Regulation FD Disclosure; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR